$2.81
Leap Therapeutics is a biotechnology business based in the US. Leap Therapeutics shares (LPTX) are listed on the NASDAQ and all prices are listed in US Dollars. Leap Therapeutics employs 54 staff and has a trailing 12-month revenue of around $375,000.
What's in this guide?
Our top picks for where to buy Leap Therapeutics stock
How to buy Leap Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – LPTX. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Leap Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Leap Therapeutics stock price (NASDAQ: LPTX)
Use our graph to track the performance of LPTX stocks over time.Leap Therapeutics shares at a glance
Latest market close | $2.81 |
---|---|
52-week range | $1.24 - $5.00 |
50-day moving average | $2.25 |
200-day moving average | $2.70 |
Wall St. target price | $11.38 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.98 |
Is it a good time to buy Leap Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Leap Therapeutics price performance over time
Historical closes compared with the close of $2.81 from 2024-09-06
1 week (2024-08-30) | -3.10% |
---|---|
1 month (2024-08-07) | 39.80% |
3 months (2024-06-07) | 25.45% |
6 months (2024-03-07) | 18.07% |
1 year (2023-09-07) | 41.21% |
---|---|
2 years (2022-09-07) | 60.57% |
3 years (2021-09-07) | 71.34% |
5 years (2019-09-06) | 74.53% |
Is Leap Therapeutics stock undervalued or overvalued?
Valuing Leap Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Leap Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Leap Therapeutics's PEG ratio
Leap Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.75. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Leap Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Leap Therapeutics financials
Revenue TTM | $375,000 |
---|---|
Gross profit TTM | $1.5 million |
Return on assets TTM | -45.62% |
Return on equity TTM | -80.54% |
Profit margin | 0% |
Book value | $1.72 |
Market Capitalization | $111 million |
TTM: trailing 12 months
Leap Therapeutics share dividends
We're not expecting Leap Therapeutics to pay a dividend over the next 12 months.
Have Leap Therapeutics's shares ever split?
Leap Therapeutics's shares were split on a 1:10 basis on 20 June 2023. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Leap Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Leap Therapeutics shares which in turn could have impacted Leap Therapeutics's share price.
Leap Therapeutics share price volatility
Over the last 12 months, Leap Therapeutics's shares have ranged in value from as little as $1.235 up to $5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Leap Therapeutics's is 0.281. This would suggest that Leap Therapeutics's shares are less volatile than average (for this exchange).
Leap Therapeutics overview
Leap Therapeutics, Inc. , a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18. 2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand.
Frequently asked questions
What percentage of Leap Therapeutics is owned by insiders or institutions?Currently 14.134% of Leap Therapeutics shares are held by insiders and 40.115% by institutions. How many people work for Leap Therapeutics?
Latest data suggests 54 work at Leap Therapeutics. When does the fiscal year end for Leap Therapeutics?
Leap Therapeutics's fiscal year ends in December. Where is Leap Therapeutics based?
Leap Therapeutics's address is: 47 Thorndike Street, Cambridge, MA, United States, 02141 What is Leap Therapeutics's ISIN number?
Leap Therapeutics's international securities identification number is: US52187K1016 What is Leap Therapeutics's CUSIP number?
Leap Therapeutics's Committee on Uniform Securities Identification Procedures number is: 52187K101
More guides on Finder
-
Options profit calculator
Use this calculator to quickly see potential outcomes of your options trades.
-
Best options trading platforms of 2024
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
-
What is a covered call?
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
-
GSD Capital review 2024
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 E*TRADE competitors worth your time
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
-
Charles Schwab vs. Fidelity
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
-
Interactive Brokers review 2024: Tailored trading and investing
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
-
Top 15 tech stocks to invest in for 2024
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Ask a question